Nasus Pharma Ltd. (NYSE: NSRX) reported positive initial results from its Phase 2 clinical trial of NS002, an investigational intranasal epinephrine powder for treating anaphylaxis.
The analysis showed that NS002 achieved significantly faster and higher early absorption of epinephrine compared to the intramuscular EpiPen® autoinjector. The company intends to start its pivotal clinical trial in the fourth quarter of 2026.
The open-label Phase 2 study included 50 healthy adults with a history of allergic rhinitis. Each participant received single and repeat doses of NS002 and intramuscular EpiPen®, both with and without a nasal allergic challenge.
This study design provided detailed data supporting NS002’s clinical effectiveness in various administration scenarios that patients might face during anaphylactic emergencies.
The Phase 2 results showed several significant benefits of NS002 across key pharmacokinetic and pharmacodynamic measures.
Dan Teleman, Chief Executive Officer of Nasus Pharma, stated, “We’ve successfully demonstrated NS002’s differentiated and potentially superior product profile compared to traditional epinephrine autoinjectors.”
 announced positive Phase 2 results for NS002, its intranasal epinephrine powder for anaphylaxis treatment.){kind=link}